 | • レポートコード：MRC2Q12-19127 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| コロナ禍により、IgA腎症治療の世界市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx％で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にIgA腎症治療のグローバル市場のxxx％を占める「コルチコステロイド」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx％CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx％のCAGRに変更されます。 IgA腎症治療の中国市場規模は2021年にUS$xxxと分析されており、アメリカとヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。アメリカの割合は2021年にxxx％であり、中国とヨーロッパはそれぞれxxx％とxxx％です。中国の割合は2028年にxxx％に達し、対象期間を通じてxxx％のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx％、xxx％、xxx％になる見通しです。ヨーロッパのIgA腎症治療市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx％になる見通しです。 IgA腎症治療のグローバル主要プレイヤーには、AstraZeneca、Johnson & Johnson Private Limited、Cipla Inc.、Hikma Pharmaceuticals PLC、Zydus Cadila、LEO Pharma A/S、Fresenius Kabi AG、Accord Healthcare、Abbott、F. Hoffmann-La Roche Ltd.、Mylan N.V.、Teva Pharmaceutical Industries Ltd.、Sanofi、Novartis AG、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma、Lupin、Alembic Pharmaceuticals Limited、Apotex Incなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 IgA腎症治療市場は、種類と用途によって区分されます。世界のIgA腎症治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。 【種類別セグメント】 コルチコステロイド、免疫抑制剤、ACE＆ARB阻害剤 【用途別セグメント】 病院、薬局、その他 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - IgA腎症治療製品概要 - 種類別市場（コルチコステロイド、免疫抑制剤、ACE＆ARB阻害剤） - 用途別市場（病院、薬局、その他） - 調査の目的 ・エグゼクティブサマリー - 世界のIgA腎症治療販売量予測2017-2028 - 世界のIgA腎症治療売上予測2017-2028 - IgA腎症治療の地域別販売量 - IgA腎症治療の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別IgA腎症治療販売量 - 主要メーカー別IgA腎症治療売上 - 主要メーカー別IgA腎症治療価格 - 競争状況の分析 - 企業M&A動向 ・種類別市場規模（コルチコステロイド、免疫抑制剤、ACE＆ARB阻害剤） - IgA腎症治療の種類別販売量 - IgA腎症治療の種類別売上 - IgA腎症治療の種類別価格 ・用途別市場規模（病院、薬局、その他） - IgA腎症治療の用途別販売量 - IgA腎症治療の用途別売上 - IgA腎症治療の用途別価格 ・北米市場 - 北米のIgA腎症治療市場規模（種類別、用途別） - 主要国別のIgA腎症治療市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパのIgA腎症治療市場規模（種類別、用途別） - 主要国別のIgA腎症治療市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋のIgA腎症治療市場規模（種類別、用途別） - 主要国別のIgA腎症治療市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米のIgA腎症治療市場規模（種類別、用途別） - 主要国別のIgA腎症治療市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカのIgA腎症治療市場規模（種類別、用途別） - 主要国別のIgA腎症治療市場規模（トルコ、サウジアラビア） ・企業情報 AstraZeneca、Johnson & Johnson Private Limited、Cipla Inc.、Hikma Pharmaceuticals PLC、Zydus Cadila、LEO Pharma A/S、Fresenius Kabi AG、Accord Healthcare、Abbott、F. Hoffmann-La Roche Ltd.、Mylan N.V.、Teva Pharmaceutical Industries Ltd.、Sanofi、Novartis AG、Sun Pharmaceutical Industries Ltd.、Aurobindo Pharma、Lupin、Alembic Pharmaceuticals Limited、Apotex Inc ・産業チェーン及び販売チャネル分析 - IgA腎症治療の産業チェーン分析 - IgA腎症治療の原材料 - IgA腎症治療の生産プロセス - IgA腎症治療の販売及びマーケティング - IgA腎症治療の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - IgA腎症治療の産業動向 - IgA腎症治療のマーケットドライバー - IgA腎症治療の課題 - IgA腎症治療の阻害要因 ・主な調査結果 |
Currently, there are two main methods for the treatment of IgA nephropathy, one is conservative therapy and the other is immunosuppressive therapy.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
Conservative treatment is the first-line treatment for patients without rapidly progressive decline in renal function. Specific measures include blood pressure control, use of RAS blockers, treatment of dyslipidemia (statins), low-salt diet (sodium <2 g/d), weight loss, smoking cessation, and avoidance of nephrotoxic drugs and nonsteroidal anti-inflammatory drugs. Corticosteroids are currently the only immunosuppressive agents with evidence to support their efficacy. In addition, the current evidence shows that mycophenolate mofetil, hydroxychloroquine, tonsillectomy, complement inhibitors and other treatments have a certain effect on IgA nephropathy, but more clinical trials are needed to verify it.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers' production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the IgA Nephropathy Treatment manufacturers, distributors, end users, industry associations, governments' industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional IgA Nephropathy Treatment market. Further, it explains the major drivers and regional dynamics of the global IgA Nephropathy Treatment market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
AstraZeneca
Johnson & Johnson Private Limited
Cipla Inc.
Hikma Pharmaceuticals PLC
Zydus Cadila
LEO Pharma A/S
Fresenius Kabi AG
Accord Healthcare
Abbott
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Alembic Pharmaceuticals Limited
Apotex Inc
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
IgA Nephropathy Treatment Segment by Type
Corticosteroids
Immunosuppressant
ACE and ARB Inhibitors
IgA Nephropathy Treatment Segment by Application
Hospital
Pharmacy
Other
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the IgA Nephropathy Treatment market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for IgA Nephropathy Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of IgA Nephropathy Treatment, also provides the sales of main regions and countries. Highlights of the upcoming market potential for IgA Nephropathy Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the IgA Nephropathy Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global IgA Nephropathy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for IgA Nephropathy Treatment sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AstraZeneca, Johnson & Johnson Private Limited, Cipla Inc., Hikma Pharmaceuticals PLC, Zydus Cadila, LEO Pharma A/S, Fresenius Kabi AG, Accord Healthcare and Abbott, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of IgA Nephropathy Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of IgA Nephropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, IgA Nephropathy Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 IgA Nephropathy Treatment Product Introduction
1.2 Market by Type
1.2.1 Global IgA Nephropathy Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Corticosteroids
1.2.3 Immunosuppressant
1.2.4 ACE and ARB Inhibitors
1.3 Market by Application
1.3.1 Global IgA Nephropathy Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global IgA Nephropathy Treatment Sales Estimates and Forecasts 2017-2028
2.2 Global IgA Nephropathy Treatment Revenue Estimates and Forecasts 2017-2028
2.3 Global IgA Nephropathy Treatment Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global IgA Nephropathy Treatment Sales by Region
2.4.1 Global IgA Nephropathy Treatment Sales by Region (2017-2022)
2.4.2 Global Sales IgA Nephropathy Treatment by Region (2023-2028)
2.5 Global IgA Nephropathy Treatment Revenue by Region
2.5.1 Global IgA Nephropathy Treatment Revenue by Region (2017-2022)
2.5.2 Global IgA Nephropathy Treatment Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global IgA Nephropathy Treatment Sales by Manufacturers
3.1.1 Global Top IgA Nephropathy Treatment Manufacturers by Sales (2017-2022)
3.1.2 Global IgA Nephropathy Treatment Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of IgA Nephropathy Treatment in 2021
3.2 Global IgA Nephropathy Treatment Revenue by Manufacturers
3.2.1 Global IgA Nephropathy Treatment Revenue by Manufacturers (2017-2022)
3.2.2 Global IgA Nephropathy Treatment Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by IgA Nephropathy Treatment Revenue in 2021
3.3 Global IgA Nephropathy Treatment Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global IgA Nephropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global IgA Nephropathy Treatment Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global IgA Nephropathy Treatment Sales by Type
4.1.1 Global IgA Nephropathy Treatment Historical Sales by Type (2017-2022)
4.1.2 Global IgA Nephropathy Treatment Forecasted Sales by Type (2023-2028)
4.1.3 Global IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
4.2 Global IgA Nephropathy Treatment Revenue by Type
4.2.1 Global IgA Nephropathy Treatment Historical Revenue by Type (2017-2022)
4.2.2 Global IgA Nephropathy Treatment Forecasted Revenue by Type (2023-2028)
4.2.3 Global IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
4.3 Global IgA Nephropathy Treatment Price by Type
4.3.1 Global IgA Nephropathy Treatment Price by Type (2017-2022)
4.3.2 Global IgA Nephropathy Treatment Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global IgA Nephropathy Treatment Sales by Application
5.1.1 Global IgA Nephropathy Treatment Historical Sales by Application (2017-2022)
5.1.2 Global IgA Nephropathy Treatment Forecasted Sales by Application (2023-2028)
5.1.3 Global IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
5.2 Global IgA Nephropathy Treatment Revenue by Application
5.2.1 Global IgA Nephropathy Treatment Historical Revenue by Application (2017-2022)
5.2.2 Global IgA Nephropathy Treatment Forecasted Revenue by Application (2023-2028)
5.2.3 Global IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
5.3 Global IgA Nephropathy Treatment Price by Application
5.3.1 Global IgA Nephropathy Treatment Price by Application (2017-2022)
5.3.2 Global IgA Nephropathy Treatment Price Forecast by Application (2023-2028)
6 North America
6.1 North America IgA Nephropathy Treatment Market Size by Type
6.1.1 North America IgA Nephropathy Treatment Sales by Type (2017-2028)
6.1.2 North America IgA Nephropathy Treatment Revenue by Type (2017-2028)
6.2 North America IgA Nephropathy Treatment Market Size by Application
6.2.1 North America IgA Nephropathy Treatment Sales by Application (2017-2028)
6.2.2 North America IgA Nephropathy Treatment Revenue by Application (2017-2028)
6.3 North America IgA Nephropathy Treatment Market Size by Country
6.3.1 North America IgA Nephropathy Treatment Sales by Country (2017-2028)
6.3.2 North America IgA Nephropathy Treatment Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe IgA Nephropathy Treatment Market Size by Type
7.1.1 Europe IgA Nephropathy Treatment Sales by Type (2017-2028)
7.1.2 Europe IgA Nephropathy Treatment Revenue by Type (2017-2028)
7.2 Europe IgA Nephropathy Treatment Market Size by Application
7.2.1 Europe IgA Nephropathy Treatment Sales by Application (2017-2028)
7.2.2 Europe IgA Nephropathy Treatment Revenue by Application (2017-2028)
7.3 Europe IgA Nephropathy Treatment Market Size by Country
7.3.1 Europe IgA Nephropathy Treatment Sales by Country (2017-2028)
7.3.2 Europe IgA Nephropathy Treatment Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific IgA Nephropathy Treatment Market Size by Type
8.1.1 Asia Pacific IgA Nephropathy Treatment Sales by Type (2017-2028)
8.1.2 Asia Pacific IgA Nephropathy Treatment Revenue by Type (2017-2028)
8.2 Asia Pacific IgA Nephropathy Treatment Market Size by Application
8.2.1 Asia Pacific IgA Nephropathy Treatment Sales by Application (2017-2028)
8.2.2 Asia Pacific IgA Nephropathy Treatment Revenue by Application (2017-2028)
8.3 Asia Pacific IgA Nephropathy Treatment Market Size by Region
8.3.1 Asia Pacific IgA Nephropathy Treatment Sales by Region (2017-2028)
8.3.2 Asia Pacific IgA Nephropathy Treatment Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America IgA Nephropathy Treatment Market Size by Type
9.1.1 Latin America IgA Nephropathy Treatment Sales by Type (2017-2028)
9.1.2 Latin America IgA Nephropathy Treatment Revenue by Type (2017-2028)
9.2 Latin America IgA Nephropathy Treatment Market Size by Application
9.2.1 Latin America IgA Nephropathy Treatment Sales by Application (2017-2028)
9.2.2 Latin America IgA Nephropathy Treatment Revenue by Application (2017-2028)
9.3 Latin America IgA Nephropathy Treatment Market Size by Country
9.3.1 Latin America IgA Nephropathy Treatment Sales by Country (2017-2028)
9.3.2 Latin America IgA Nephropathy Treatment Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa IgA Nephropathy Treatment Market Size by Type
10.1.1 Middle East and Africa IgA Nephropathy Treatment Sales by Type (2017-2028)
10.1.2 Middle East and Africa IgA Nephropathy Treatment Revenue by Type (2017-2028)
10.2 Middle East and Africa IgA Nephropathy Treatment Market Size by Application
10.2.1 Middle East and Africa IgA Nephropathy Treatment Sales by Application (2017-2028)
10.2.2 Middle East and Africa IgA Nephropathy Treatment Revenue by Application (2017-2028)
10.3 Middle East and Africa IgA Nephropathy Treatment Market Size by Country
10.3.1 Middle East and Africa IgA Nephropathy Treatment Sales by Country (2017-2028)
10.3.2 Middle East and Africa IgA Nephropathy Treatment Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Corporation Information
11.1.2 AstraZeneca Overview
11.1.3 AstraZeneca IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 AstraZeneca IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 AstraZeneca Recent Developments
11.2 Johnson & Johnson Private Limited
11.2.1 Johnson & Johnson Private Limited Corporation Information
11.2.2 Johnson & Johnson Private Limited Overview
11.2.3 Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Johnson & Johnson Private Limited IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Johnson & Johnson Private Limited Recent Developments
11.3 Cipla Inc.
11.3.1 Cipla Inc. Corporation Information
11.3.2 Cipla Inc. Overview
11.3.3 Cipla Inc. IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cipla Inc. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cipla Inc. Recent Developments
11.4 Hikma Pharmaceuticals PLC
11.4.1 Hikma Pharmaceuticals PLC Corporation Information
11.4.2 Hikma Pharmaceuticals PLC Overview
11.4.3 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Hikma Pharmaceuticals PLC Recent Developments
11.5 Zydus Cadila
11.5.1 Zydus Cadila Corporation Information
11.5.2 Zydus Cadila Overview
11.5.3 Zydus Cadila IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Zydus Cadila IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Zydus Cadila Recent Developments
11.6 LEO Pharma A/S
11.6.1 LEO Pharma A/S Corporation Information
11.6.2 LEO Pharma A/S Overview
11.6.3 LEO Pharma A/S IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 LEO Pharma A/S IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 LEO Pharma A/S Recent Developments
11.7 Fresenius Kabi AG
11.7.1 Fresenius Kabi AG Corporation Information
11.7.2 Fresenius Kabi AG Overview
11.7.3 Fresenius Kabi AG IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Fresenius Kabi AG IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Fresenius Kabi AG Recent Developments
11.8 Accord Healthcare
11.8.1 Accord Healthcare Corporation Information
11.8.2 Accord Healthcare Overview
11.8.3 Accord Healthcare IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 Accord Healthcare IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 Accord Healthcare Recent Developments
11.9 Abbott
11.9.1 Abbott Corporation Information
11.9.2 Abbott Overview
11.9.3 Abbott IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Abbott IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Abbott Recent Developments
11.10 F. Hoffmann-La Roche Ltd.
11.10.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.10.2 F. Hoffmann-La Roche Ltd. Overview
11.10.3 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 F. Hoffmann-La Roche Ltd. Recent Developments
11.11 Mylan N.V.
11.11.1 Mylan N.V. Corporation Information
11.11.2 Mylan N.V. Overview
11.11.3 Mylan N.V. IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Mylan N.V. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Mylan N.V. Recent Developments
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Corporation Information
11.12.2 Teva Pharmaceutical Industries Ltd. Overview
11.12.3 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Developments
11.13 Sanofi
11.13.1 Sanofi Corporation Information
11.13.2 Sanofi Overview
11.13.3 Sanofi IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.13.4 Sanofi IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.13.5 Sanofi Recent Developments
11.14 Novartis AG
11.14.1 Novartis AG Corporation Information
11.14.2 Novartis AG Overview
11.14.3 Novartis AG IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.14.4 Novartis AG IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.14.5 Novartis AG Recent Developments
11.15 Sun Pharmaceutical Industries Ltd.
11.15.1 Sun Pharmaceutical Industries Ltd. Corporation Information
11.15.2 Sun Pharmaceutical Industries Ltd. Overview
11.15.3 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.15.4 Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.15.5 Sun Pharmaceutical Industries Ltd. Recent Developments
11.16 Aurobindo Pharma
11.16.1 Aurobindo Pharma Corporation Information
11.16.2 Aurobindo Pharma Overview
11.16.3 Aurobindo Pharma IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.16.4 Aurobindo Pharma IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.16.5 Aurobindo Pharma Recent Developments
11.17 Lupin
11.17.1 Lupin Corporation Information
11.17.2 Lupin Overview
11.17.3 Lupin IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.17.4 Lupin IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.17.5 Lupin Recent Developments
11.18 Alembic Pharmaceuticals Limited
11.18.1 Alembic Pharmaceuticals Limited Corporation Information
11.18.2 Alembic Pharmaceuticals Limited Overview
11.18.3 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.18.4 Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.18.5 Alembic Pharmaceuticals Limited Recent Developments
11.19 Apotex Inc
11.19.1 Apotex Inc Corporation Information
11.19.2 Apotex Inc Overview
11.19.3 Apotex Inc IgA Nephropathy Treatment Sales, Price, Revenue and Gross Margin (2017-2022)
11.19.4 Apotex Inc IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
11.19.5 Apotex Inc Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 IgA Nephropathy Treatment Industry Chain Analysis
12.2 IgA Nephropathy Treatment Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 IgA Nephropathy Treatment Production Mode & Process
12.4 IgA Nephropathy Treatment Sales and Marketing
12.4.1 IgA Nephropathy Treatment Sales Channels
12.4.2 IgA Nephropathy Treatment Distributors
12.5 IgA Nephropathy Treatment Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 IgA Nephropathy Treatment Industry Trends
13.2 IgA Nephropathy Treatment Market Drivers
13.3 IgA Nephropathy Treatment Market Challenges
13.4 IgA Nephropathy Treatment Market Restraints
14 Key Findings in The Global IgA Nephropathy Treatment Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
Table 1. Global IgA Nephropathy Treatment Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Corticosteroids
Table 3. Major Manufacturers of Immunosuppressant
Table 4. Major Manufacturers of ACE and ARB Inhibitors
Table 5. Global IgA Nephropathy Treatment Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 6. Global IgA Nephropathy Treatment Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 7. Global IgA Nephropathy Treatment Sales by Region (2017-2022) & (K Units)
Table 8. Global IgA Nephropathy Treatment Sales Market Share by Region (2017-2022)
Table 9. Global IgA Nephropathy Treatment Sales by Region (2023-2028) & (K Units)
Table 10. Global IgA Nephropathy Treatment Sales Market Share by Region (2023-2028)
Table 11. Global IgA Nephropathy Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 12. Global IgA Nephropathy Treatment Revenue Market Share by Region (2017-2022)
Table 13. Global IgA Nephropathy Treatment Revenue by Region (2023-2028) & (US$ Million)
Table 14. Global IgA Nephropathy Treatment Revenue Market Share by Region (2023-2028)
Table 15. Global IgA Nephropathy Treatment Sales by Manufacturers (2017-2022) & (K Units)
Table 16. Global IgA Nephropathy Treatment Sales Share by Manufacturers (2017-2022)
Table 17. Global IgA Nephropathy Treatment Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 18. Global IgA Nephropathy Treatment Revenue Share by Manufacturers (2017-2022)
Table 19. IgA Nephropathy Treatment Price by Manufacturers (2017-2022) &(US$/Unit)
Table 20. Global IgA Nephropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 21. Global IgA Nephropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in IgA Nephropathy Treatment as of 2021)
Table 22. IgA Nephropathy Treatment Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers IgA Nephropathy Treatment Product Offered
Table 24. Date of Manufacturers Enter into IgA Nephropathy Treatment Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 27. Global IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 28. Global IgA Nephropathy Treatment Sales Share by Type (2017-2022)
Table 29. Global IgA Nephropathy Treatment Sales Share by Type (2023-2028)
Table 30. Global IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 31. Global IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 32. Global IgA Nephropathy Treatment Revenue Share by Type (2017-2022)
Table 33. Global IgA Nephropathy Treatment Revenue Share by Type (2023-2028)
Table 34. IgA Nephropathy Treatment Price by Type (2017-2022) & (US$/Unit)
Table 35. Global IgA Nephropathy Treatment Price Forecast by Type (2023-2028) & (US$/Unit)
Table 36. Global IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 37. Global IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 38. Global IgA Nephropathy Treatment Sales Share by Application (2017-2022)
Table 39. Global IgA Nephropathy Treatment Sales Share by Application (2023-2028)
Table 40. Global IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 41. Global IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 42. Global IgA Nephropathy Treatment Revenue Share by Application (2017-2022)
Table 43. Global IgA Nephropathy Treatment Revenue Share by Application (2023-2028)
Table 44. IgA Nephropathy Treatment Price by Application (2017-2022) & (US$/Unit)
Table 45. Global IgA Nephropathy Treatment Price Forecast by Application (2023-2028) & (US$/Unit)
Table 46. North America IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 47. North America IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 48. North America IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 49. North America IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 50. North America IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 51. North America IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 52. North America IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 53. North America IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 54. North America IgA Nephropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 55. North America IgA Nephropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 56. North America IgA Nephropathy Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 57. North America IgA Nephropathy Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 58. Europe IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 59. Europe IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 60. Europe IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 61. Europe IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 62. Europe IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 63. Europe IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 64. Europe IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 65. Europe IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 66. Europe IgA Nephropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 67. Europe IgA Nephropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 68. Europe IgA Nephropathy Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 69. Europe IgA Nephropathy Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 70. Asia Pacific IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 71. Asia Pacific IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 72. Asia Pacific IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 73. Asia Pacific IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 74. Asia Pacific IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 75. Asia Pacific IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 76. Asia Pacific IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 77. Asia Pacific IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 78. Asia Pacific IgA Nephropathy Treatment Sales by Region (2017-2022) & (K Units)
Table 79. Asia Pacific IgA Nephropathy Treatment Sales by Region (2023-2028) & (K Units)
Table 80. Asia Pacific IgA Nephropathy Treatment Revenue by Region (2017-2022) & (US$ Million)
Table 81. Asia Pacific IgA Nephropathy Treatment Revenue by Region (2023-2028) & (US$ Million)
Table 82. Latin America IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 83. Latin America IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 84. Latin America IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 85. Latin America IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 86. Latin America IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 87. Latin America IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 88. Latin America IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 89. Latin America IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 90. Latin America IgA Nephropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 91. Latin America IgA Nephropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 92. Latin America IgA Nephropathy Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 93. Latin America IgA Nephropathy Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 94. Middle East and Africa IgA Nephropathy Treatment Sales by Type (2017-2022) & (K Units)
Table 95. Middle East and Africa IgA Nephropathy Treatment Sales by Type (2023-2028) & (K Units)
Table 96. Middle East and Africa IgA Nephropathy Treatment Revenue by Type (2017-2022) & (US$ Million)
Table 97. Middle East and Africa IgA Nephropathy Treatment Revenue by Type (2023-2028) & (US$ Million)
Table 98. Middle East and Africa IgA Nephropathy Treatment Sales by Application (2017-2022) & (K Units)
Table 99. Middle East and Africa IgA Nephropathy Treatment Sales by Application (2023-2028) & (K Units)
Table 100. Middle East and Africa IgA Nephropathy Treatment Revenue by Application (2017-2022) & (US$ Million)
Table 101. Middle East and Africa IgA Nephropathy Treatment Revenue by Application (2023-2028) & (US$ Million)
Table 102. Middle East and Africa IgA Nephropathy Treatment Sales by Country (2017-2022) & (K Units)
Table 103. Middle East and Africa IgA Nephropathy Treatment Sales by Country (2023-2028) & (K Units)
Table 104. Middle East and Africa IgA Nephropathy Treatment Revenue by Country (2017-2022) & (US$ Million)
Table 105. Middle East and Africa IgA Nephropathy Treatment Revenue by Country (2023-2028) & (US$ Million)
Table 106. AstraZeneca Corporation Information
Table 107. AstraZeneca Description and Major Businesses
Table 108. AstraZeneca IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 109. AstraZeneca IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 110. AstraZeneca Recent Developments
Table 111. Johnson & Johnson Private Limited Corporation Information
Table 112. Johnson & Johnson Private Limited Description and Major Businesses
Table 113. Johnson & Johnson Private Limited IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 114. Johnson & Johnson Private Limited IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 115. Johnson & Johnson Private Limited Recent Developments
Table 116. Cipla Inc. Corporation Information
Table 117. Cipla Inc. Description and Major Businesses
Table 118. Cipla Inc. IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 119. Cipla Inc. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 120. Cipla Inc. Recent Developments
Table 121. Hikma Pharmaceuticals PLC Corporation Information
Table 122. Hikma Pharmaceuticals PLC Description and Major Businesses
Table 123. Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 124. Hikma Pharmaceuticals PLC IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 125. Hikma Pharmaceuticals PLC Recent Developments
Table 126. Zydus Cadila Corporation Information
Table 127. Zydus Cadila Description and Major Businesses
Table 128. Zydus Cadila IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 129. Zydus Cadila IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 130. Zydus Cadila Recent Developments
Table 131. LEO Pharma A/S Corporation Information
Table 132. LEO Pharma A/S Description and Major Businesses
Table 133. LEO Pharma A/S IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 134. LEO Pharma A/S IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 135. LEO Pharma A/S Recent Developments
Table 136. Fresenius Kabi AG Corporation Information
Table 137. Fresenius Kabi AG Description and Major Businesses
Table 138. Fresenius Kabi AG IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 139. Fresenius Kabi AG IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 140. Fresenius Kabi AG Recent Developments
Table 141. Accord Healthcare Corporation Information
Table 142. Accord Healthcare Description and Major Businesses
Table 143. Accord Healthcare IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 144. Accord Healthcare IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 145. Accord Healthcare Recent Developments
Table 146. Abbott Corporation Information
Table 147. Abbott Description and Major Businesses
Table 148. Abbott IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 149. Abbott IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 150. Abbott Recent Developments
Table 151. F. Hoffmann-La Roche Ltd. Corporation Information
Table 152. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 153. F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 154. F. Hoffmann-La Roche Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 155. F. Hoffmann-La Roche Ltd. Recent Developments
Table 156. Mylan N.V. Corporation Information
Table 157. Mylan N.V. Description and Major Businesses
Table 158. Mylan N.V. IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 159. Mylan N.V. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 160. Mylan N.V. Recent Developments
Table 161. Teva Pharmaceutical Industries Ltd. Corporation Information
Table 162. Teva Pharmaceutical Industries Ltd. Description and Major Businesses
Table 163. Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 164. Teva Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 165. Teva Pharmaceutical Industries Ltd. Recent Developments
Table 166. Sanofi Corporation Information
Table 167. Sanofi Description and Major Businesses
Table 168. Sanofi IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 169. Sanofi IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 170. Sanofi Recent Developments
Table 171. Novartis AG Corporation Information
Table 172. Novartis AG Description and Major Businesses
Table 173. Novartis AG IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 174. Novartis AG IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 175. Novartis AG Recent Developments
Table 176. Sun Pharmaceutical Industries Ltd. Corporation Information
Table 177. Sun Pharmaceutical Industries Ltd. Description and Major Businesses
Table 178. Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 179. Sun Pharmaceutical Industries Ltd. IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 180. Sun Pharmaceutical Industries Ltd. Recent Developments
Table 181. Aurobindo Pharma Corporation Information
Table 182. Aurobindo Pharma Description and Major Businesses
Table 183. Aurobindo Pharma IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 184. Aurobindo Pharma IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 185. Aurobindo Pharma Recent Developments
Table 186. Lupin Corporation Information
Table 187. Lupin Description and Major Businesses
Table 188. Lupin IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 189. Lupin IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 190. Lupin Recent Developments
Table 191. Alembic Pharmaceuticals Limited Corporation Information
Table 192. Alembic Pharmaceuticals Limited Description and Major Businesses
Table 193. Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 194. Alembic Pharmaceuticals Limited IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 195. Alembic Pharmaceuticals Limited Recent Developments
Table 196. Apotex Inc Corporation Information
Table 197. Apotex Inc Description and Major Businesses
Table 198. Apotex Inc IgA Nephropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022)
Table 199. Apotex Inc IgA Nephropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications
Table 200. Apotex Inc Recent Developments
Table 201. Key Raw Materials Lists
Table 202. Raw Materials Key Suppliers Lists
Table 203. IgA Nephropathy Treatment Distributors List
Table 204. IgA Nephropathy Treatment Customers List
Table 205. IgA Nephropathy Treatment Market Trends
Table 206. IgA Nephropathy Treatment Market Drivers
Table 207. IgA Nephropathy Treatment Market Challenges
Table 208. IgA Nephropathy Treatment Market Restraints
Table 209. Research Programs/Design for This Report
Table 210. Key Data Information from Secondary Sources
Table 211. Key Data Information from Primary Sources
List of Figures
Figure 1. IgA Nephropathy Treatment Product Picture
Figure 2. Global IgA Nephropathy Treatment Market Share by Type in 2021 & 2028
Figure 3. Corticosteroids Product Picture
Figure 4. Immunosuppressant Product Picture
Figure 5. ACE and ARB Inhibitors Product Picture
Figure 6. Global IgA Nephropathy Treatment Market Share by Application in 2021 & 2028
Figure 7. Hospital
Figure 8. Pharmacy
Figure 9. Other
Figure 10. IgA Nephropathy Treatment Report Years Considered
Figure 11. Global IgA Nephropathy Treatment Sales 2017-2028 (K Units)
Figure 12. Global IgA Nephropathy Treatment Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 13. Global IgA Nephropathy Treatment Revenue 2017-2028 (US$ Million)
Figure 14. Global IgA Nephropathy Treatment Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 15. Global IgA Nephropathy Treatment Sales Market Share by Region (2017-2022)
Figure 16. Global IgA Nephropathy Treatment Sales Market Share by Region (2023-2028)
Figure 17. North America IgA Nephropathy Treatment Sales YoY (2017-2028) & (K Units)
Figure 18. North America IgA Nephropathy Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 19. Europe IgA Nephropathy Treatment Sales YoY (2017-2028) & (K Units)
Figure 20. Europe IgA Nephropathy Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 21. Asia-Pacific IgA Nephropathy Treatment Sales YoY (2017-2028) & (K Units)
Figure 22. Asia-Pacific IgA Nephropathy Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 23. Latin America IgA Nephropathy Treatment Sales YoY (2017-2028) & (K Units)
Figure 24. Latin America IgA Nephropathy Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Middle East & Africa IgA Nephropathy Treatment Sales YoY (2017-2028) & (K Units)
Figure 26. Middle East & Africa IgA Nephropathy Treatment Revenue YoY (2017-2028) & (US$ Million)
Figure 27. The IgA Nephropathy Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 28. The Top 5 and 10 Largest Manufacturers of IgA Nephropathy Treatment in the World: Market Share by IgA Nephropathy Treatment Revenue in 2021
Figure 29. Global IgA Nephropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 30. Global IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 31. Global IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 32. Global IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 33. Global IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 34. North America IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 35. North America IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 36. North America IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 37. North America IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 38. North America IgA Nephropathy Treatment Sales Share by Country (2017-2028)
Figure 39. North America IgA Nephropathy Treatment Revenue Share by Country (2017-2028)
Figure 40. United States IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 41. Canada IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 42. Europe IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 43. Europe IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 44. Europe IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 45. Europe IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 46. Europe IgA Nephropathy Treatment Sales Share by Country (2017-2028)
Figure 47. Europe IgA Nephropathy Treatment Revenue Share by Country (2017-2028)
Figure 48. Germany IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 49. France IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 50. U.K. IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 51. Italy IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 52. Russia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 53. Asia Pacific IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 54. Asia Pacific IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 55. Asia Pacific IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 56. Asia Pacific IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 57. Asia Pacific IgA Nephropathy Treatment Sales Share by Region (2017-2028)
Figure 58. Asia Pacific IgA Nephropathy Treatment Revenue Share by Region (2017-2028)
Figure 59. China IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 60. Japan IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 61. South Korea IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 62. India IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 63. Australia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 64. China Taiwan IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 65. Indonesia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 66. Thailand IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 67. Malaysia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 68. Latin America IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 69. Latin America IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 70. Latin America IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 71. Latin America IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 72. Latin America IgA Nephropathy Treatment Sales Share by Country (2017-2028)
Figure 73. Latin America IgA Nephropathy Treatment Revenue Share by Country (2017-2028)
Figure 74. Mexico IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 75. Brazil IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 76. Argentina IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 77. Colombia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 78. Middle East and Africa IgA Nephropathy Treatment Sales Market Share by Type (2017-2028)
Figure 79. Middle East and Africa IgA Nephropathy Treatment Revenue Market Share by Type (2017-2028)
Figure 80. Middle East and Africa IgA Nephropathy Treatment Sales Market Share by Application (2017-2028)
Figure 81. Middle East and Africa IgA Nephropathy Treatment Revenue Market Share by Application (2017-2028)
Figure 82. Middle East and Africa IgA Nephropathy Treatment Sales Share by Country (2017-2028)
Figure 83. Middle East and Africa IgA Nephropathy Treatment Revenue Share by Country (2017-2028)
Figure 84. Turkey IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 85. Saudi Arabia IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 86. UAE IgA Nephropathy Treatment Revenue (2017-2028) & (US$ Million)
Figure 87. IgA Nephropathy Treatment Value Chain
Figure 88. IgA Nephropathy Treatment Production Process
Figure 89. Channels of Distribution
Figure 90. Distributors Profiles
Figure 91. Bottom-up and Top-down Approaches for This Report
Figure 92. Data Triangulation
Figure 93. Key Executives Interviewed